Gaithersburg, MD, United States of America

Ching Ching Leow

This inventor holds 10 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Medimmune Limited, University of Helsinki. Active years: 2018-2026.

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 90.0

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 10.6

ph-index = 2

Forward Citations = 25(Granted Patents)

Company Filing History:

University of Helsinki

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630648 - BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF (2026-05-19),

2. 11634483 - Nucleic acids encoding anti-VEGF-A antibodies and uses thereof (2023-04-25),

3. 11566068 - Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof (2023-01-31),

4. 11525012 - Binding molecules specific for CD73 and uses thereof (2022-12-13),

5. 10919958 - Anti-VEGF-A antibodies and uses thereof (2021-02-16),

6. 10836819 - Anti-VEGF-A and anti-ANG2 antibodies and uses thereof (2020-11-17),

7. 10556968 - Binding molecules specific for CD73 and uses thereof (2020-02-11),

8. 10400035 - Methods of protecting a solid organ transplant tissue with angiopoietin-2 antibodies (2019-09-03),

9. 10287362 - Binding molecules specific for CD73 and uses thereof (2019-05-14),

10. 9938356 - Binding molecules specific for CD73 and uses thereof (2018-04-10),

Title: Innovations by Ching Ching Leow

Introduction

Ching Ching Leow is a notable inventor based in Gaithersburg, MD (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting vascular endothelial growth factor (VEGF). With a total of nine patents to her name, her work has the potential to impact therapeutic approaches in various medical conditions.

Latest Patents

Among her latest patents is one titled "Nucleic acids encoding anti-VEGF-A antibodies and uses thereof." This invention relates to antibodies that exhibit activity against VEGF, along with methods for their production and application. Another significant patent is "Nucleic acids encoding bispecific anti-VEGF and anti-ANG2 antibodies and uses thereof." This invention focuses on bispecific antibodies that target both VEGF and angiopoietin (ANG), providing innovative methods for their creation and utilization.

Career Highlights

Ching Ching Leow has worked with prominent organizations such as MedImmune Limited and the University of Helsinki. Her experience in these institutions has allowed her to collaborate on groundbreaking research and development projects in the field of biotechnology.

Collaborations

Some of her notable coworkers include Carl Hay and Kris Sachsenmeier. Their collaborative efforts have contributed to the advancement of her research and the successful development of her patented technologies.

Conclusion

Ching Ching Leow's innovative work in the field of biotechnology, particularly in the development of antibodies, showcases her significant contributions to medical science. Her patents reflect her dedication to advancing therapeutic options for various health conditions.